Skip to main content
. 2022 May 25;6(6):427–433. doi: 10.1002/jgh3.12772

Figure 2.

Figure 2

Overall survival in patients who received lenvatinib (a) according to the use of post‐progression therapy and (b) according to whether use of an immune checkpoint inhibitor (ICI) as post‐progression therapy compared with patients who received other therapies.